Latest / Eyewire News: The Podcast

Harrow Adds Biosimilars to US Portfolio
Harrow enters a deal to expand it biosimilar pharma portfolio; the first gene-agnostic therapy to restore vision in RP patients advances; and Aldeyra provides an update on its dry eye drug candidate reproxalap.
Learn more about your ad choices. Visit megaphone.fm/adchoices
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.